Clinical application and short-term follow-up study of minimally invasive transcatheter patent foramen ovale occlusion
10.3760/cma.j.cn112434-20240926-00231
- VernacularTitle:极简式经导管卵圆孔未闭封堵术的临床应用及短期随访研究
- Author:
Qiuming HU
1
;
Kaisheng WU
1
;
Wenbo ZHANG
1
;
Zonghao CHEN
1
;
Jie HAN
1
;
Ming GONG
1
Author Information
1. 首都医科大学附属北京安贞医院心脏外科,北京 100029
- Publication Type:Journal Article
- Keywords:
Patent foramen ovale;
Transcatheter patent foramen ovale occlusion;
Minimally invasive;
Stroke;
Migraine
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2025;41(2):65-71
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety and effectiveness of the clinical application of minimally invasive transcatheter patent foramen ovale occlusion.Methods:A total of 123 patients who underwent transcatheter patent foramen ovale (PFO) occlusion at the Department of Cardiac Surgery of Beijing Anzhen Hospital from January 1, 2023, to December 31, 2023, were retrospectively analyzed. According to the surgical protocol, this study divided the patients into the conventional occlusion group (Group A, 53 cases) and the minimal invasive occlusion group (Group B, 70 cases). The patients were followed up for at least six months after surgery to evaluate the safety and effectiveness of the new method.Results:The surgical success rate was 100% in both groups. Intraoperative fluoroscopy time decreased by over 50% (7 min in group A and 3 min in group B, P<0.001). At the six-month postoperative follow-up, contrast-enhanced transcranial Doppler ultrasound sonography revealed seven positive results, two of which indicated large shunts. It was further reviewed for combined pulmonary arteriovenous fistula. One patient experienced a recurrence of stroke after the surgery. The patients' overall migraine and transient ischemia attack (TIA) were significantly relieved, and their overall VAS scores decreased significantly compared to the previous ones. Conclusion:The minimally invasive transcatheter PFO occlusion procedure is safe, reliable, and cost-effective. It warrants further follow-up and promotion. Meanwhile, transcatheter PFO occlusion is an effective treatment for preventing recurrent stroke and relieving symptoms like migraine and TIA in patients.